Goldman Sachs crosses Evotec voting thresholds
Analysis based on 15 articles · First reported Aug 31, 2026 · Last updated Sep 08, 2026
The announcements are routine regulatory disclosures and are unlikely to have a significant impact on Evotec's stock price or Goldman Sachs' operations. The slight changes in voting rights reflect normal portfolio adjustments by a major institutional investor.
Goldman Sachs, Inc. has disclosed changes in its voting rights in Evotec SE, a German pharmaceutical company, through regulatory filings under the German Securities Trading Act (WpHG). On 24 August 2026, Goldman Sachs crossed a threshold, reporting total voting rights of 13.90% (0.07% shares and 13.83% through instruments). Subsequently, on 3 September 2026, another threshold was crossed, with total voting rights at 13.79% (0.43% shares and 13.36% through instruments). The notifications were made voluntarily at the subsidiary level and reflect adjustments in Goldman Sachs' holdings, including shares, convertible bonds, swaps, and other instruments. These filings are routine regulatory disclosures and do not indicate any change in control or strategic intent.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard